A phase I study of immunostimulation and toxicity in patients with colorectal carcinoma using the immunomodulator 3,6-bis(2-piperidinoethoxy) acridine trihydrochloride (CL 246738).
Seventeen patients with residual or recurrent colorectal carcinoma were given a new synthetic immunomodulator [3,6-bis(2-piperidinoethoxy) acridine trihydrochloride CL246738) as part of a phase I clinical trial. No patients had undergone previous immunotherapy or chemotherapy. Detailed immunological studies including interferon levels, interleukin 2 levels, natural killer cell function, mitogen responses of lymphocytes, immunoglobulin levels and lymphocyte subpopulation levels were analysed in the patients who received this drug in an attempt to find out whether there was any biological activity identifiable in humans. None of the subjects showed any significant increases in post treatment values of the immunological parameters studied. Toxic effects of the drug at high doses included nausea, diarrhoea and decreased levels of consciousness. In conclusion, no immunological effects were identified following the administration of CL 246738 in human subjects with recurrent or residual colorectal cancer.
Lennard
T W
TW
Department of Surgery, University of Newcastle upon Tyne, U.K.
Harris
A L
AL
Hales
J
J
Dickinson
A
A
Wolstencroft
R
R
Halcrow
P
P
Shenton
B K
BK
McDonald
M
M
Lawrence
G F
GF
Taylor
R M
RM
D000166:Acridines / Q000009:adverse effects / Q000627:therapeutic use*; D000230:Adenocarcinoma / Q000188:drug therapy*; D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D000166:Acridines; D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; C045570:3,6-bis(2-piperidinoethoxy)acridine trihydrochloride